Begin main content

erenumab

Last Updated: August 15, 2019
Result type: Reports
Project Number: SR0578-000
Product Line: Common Drug Review

Generic Name: erenumab

Brand Name: Aimovig

Manufacturer: Novartis Pharmaceuticals Canada Inc.

Indications: Migraine

Manufacturer Requested Reimbursement Criteria1: For prevention of migraine in adults who have at least 8 migraine days per month and who have previously failed, are intolerant, or have a contraindication to at least two migraine preventive therapies

Submission Type: New

Project Status: Active

Biosimilar: No

Fee Schedule: Schedule A

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient input postedApril 04, 2019
Clarification:

CADTH initially posted the call for patient from July 12, 2018 to August 31, 2018. The pending submission was subsequently delayed and CADTH re-posted the call for patient input when the revised filing date was received.

Patient group input closedMay 27, 2019
Clarification:

- Patient input submission received from Migraine Canada Migraine Quebec

Patient input summary sent for review to patient input groupsJune 03, 2019
Patient group comments on input summary closedJune 10, 2019
Clarification:

- Patient input summary feedback received

Submission receivedMay 02, 2019
Submission accepted for reviewMay 16, 2019
Review initiatedMay 17, 2019
Draft CADTH review report(s) sent to applicantAugust 01, 2019
Comments from applicant on draft CADTH review report(s) receivedAugust 13, 2019
CADTH review team's comments on draft CADTH review report(s) sent to applicantOctober 03, 2019
Canadian Drug Expert Committee (CDEC) meetingOctober 16, 2019
CDEC recommendation sent to applicant and drug plansOctober 28, 2019
To
October 30, 2019